Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment

NCT04166942 is registered in ClinicalTrials.gov with Kadmon, a Sanofi Company as lead sponsor.

NCT NCT04166942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04166942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment
Lead sponsor
Kadmon, a Sanofi Company
Phase
Phase 1
Overall status
Completed
Start date
December 11, 2019
Completion date
June 6, 2022
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment